Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
Phase 1
Recruiting
Conditions
Locally Advanced, Recurrent or Metastatic Malignancies
Interventions
Drug: SSGJ-705
Subscribe
First Posted Date
2024-04-30
Last Posted Date
2024-10-18
Lead Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Target Recruit Count
180
Registration Number
NCT06390774
Locations
🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy